Methyldopa Prices, Trend, Chart, Market Analysis, News, Demand, Historical and Forecast Data Report 2025 Edition
Methyldopa Price Trend, Index and Forecast
Track the latest insights on methyldopa price trend and forecast with detailed analysis of regional fluctuations and market dynamics across North America, Latin America, Central Europe, Western Europe, Eastern Europe, Middle East, North Africa, West Africa, Central and Southern Africa, Central Asia, Southeast Asia, South Asia, East Asia, and Oceania.
Methyldopa Prices Outlook Q3 2025
- USA: USD 175543/MT
- China: USD 142662/MT
- Germany: USD 160128/MT
- Japan: USD 184782/MT
- Brazil: USD 167838/MT
Methyldopa Price Chart
Get real-time access to monthly/quarterly/yearly prices Request Sample
During the third quarter of 2025, the methyldopa prices in the USA reached 175543 USD/MT in September. The upward movement in prices was primarily driven by firm domestic pharmaceutical demand supported by stable prescription volumes for antihypertensive drugs. Production rates remained controlled as manufacturers balanced inventory levels to avoid oversupply. Elevated compliance costs and quality assurance requirements also supported higher price levels.
During the third quarter of 2025, the methyldopa prices in China reached 142662 USD/MT in September. Prices softened due to subdued export demand and sufficient availability from domestic producers. Manufacturing plants operated at steady utilization rates, leading to comfortable inventory positions. Reduced procurement activity from overseas buyers weakened negotiating power for sellers. Additionally, stable raw material access limited cost pressures, allowing producers to offer competitive pricing.
During the third quarter of 2025, the methyldopa prices in Germany reached 160128 USD/MT in September. The market experienced downward pressure due to slower pharmaceutical formulation demand and adequate supply levels. Imports from Asian producers increased availability, intensifying competition among suppliers. Buyers delayed bulk purchases, expecting further price corrections. Regulatory compliance costs remained stable, offering limited cost-side support.
During the third quarter of 2025, the methyldopa prices in Japan reached 184782 USD/MT in September. Prices strengthened due to steady domestic pharmaceutical consumption and limited import availability. Supply constraints emerged as manufacturers maintained conservative output levels to manage operational costs. Buyers favored long-term contracts, supporting price stability. Elevated quality standards and compliance requirements added to production costs, reinforcing price increases.
During the third quarter of 2025, the methyldopa prices in Brazil reached 167838 USD/MT in September. Prices declined due to weakened pharmaceutical demand and ample import availability. Buyers adopted a wait-and-see approach, limiting spot purchases. Improved logistics efficiency reduced supply bottlenecks, easing market tightness. Competitive pressure from international suppliers further pushed prices lower.
Methyldopa Prices Outlook Q2 2025
- USA: USD 170100/MT
- China: USD 144688/MT
- Germany: USD 163898/MT
- Japan: USD 178706/MT
- Brazil: USD 174286/MT
During the second quarter of 2025, the methyldopa prices in the USA reached 170100 USD/MT in June. Pricing levels were shaped by consistent procurement from pharmaceutical manufacturers supplying antihypertensive formulations. Producers maintained disciplined operating schedules aligned with contract-based demand, ensuring predictable supply availability. Compliance with regulatory standards and quality assurance protocols continued to influence production costs.
During the second quarter of 2025, the methyldopa prices in China reached 144688 USD/MT in June. Market pricing reflected sufficient domestic production and reliable access to pharmaceutical-grade raw materials. Export participation remained selective, with buyers focusing on cost efficiency and contract fulfillment. Inventory levels at manufacturing sites allowed suppliers flexibility in negotiations.
During the second quarter of 2025, the methyldopa prices in Germany reached 163898 USD/MT in June. Prices were influenced by regulated pharmaceutical demand and continuous inflow of imported material. Buyers emphasized compliance, traceability, and supplier reliability in procurement decisions. Manufacturers and distributors operated with planned inventory coverage to support healthcare supply chains.
During the second quarter of 2025, the methyldopa prices in Japan reached 178706 USD/MT in June. Pricing dynamics were shaped by domestic pharmaceutical consumption and adherence to strict manufacturing standards. Import volumes were aligned with forecasted healthcare requirements. Producers maintained controlled output to meet quality benchmarks. Buyers favored contractual sourcing to ensure consistency, while logistics planning supported timely delivery.
During the second quarter of 2025, the methyldopa prices in Brazil reached 174286 USD/MT in June. Market pricing was influenced by pharmaceutical sector demand and readily available imported supply. Distributors focused on inventory optimization and turnover management. Buyers assessed procurement needs carefully amid broader healthcare budgeting considerations. Improved logistics coordination supported supply accessibility.
Regional Coverage
The report provides a detailed analysis of the market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of FOB and CIF prices, as well as the key factors influencing methyldopa prices.
Europe Methyldopa Price Trend
Q3 2025:
The methyldopa price index trends in Europe reflected a generally bearish market environment shaped by restrained pharmaceutical procurement across major economies. Demand from formulation units remained limited as healthcare distributors relied on existing inventories rather than entering fresh contracts. Adequate availability from international suppliers ensured uninterrupted supply flows, intensifying competition among regional distributors. Import volumes remained well aligned with consumption requirements, preventing supply-side tightness.
Q2 2025:
Methyldopa price index trends in Europe reflected pricing shaped by regulated pharmaceutical consumption and structured supply availability across the region. Healthcare systems maintained predictable procurement cycles, supporting consistent demand from formulation and distribution channels. Imports from global producers ensured broad material accessibility, allowing buyers to select suppliers based on compliance history and quality credentials. Procurement decisions emphasized regulatory adherence, documentation transparency, and supplier accreditation, which remained central to sourcing strategies.
This analysis can be extended to include detailed methyldopa price information for a comprehensive list of countries.
| Region | Countries Covered |
|---|---|
| Europe | Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal, and Greece, among other European countries. |
North America Methyldopa Price Trend
Q3 2025:
Methyldopa price index movements in North America indicated an upward pricing trend supported by structured pharmaceutical demand and disciplined supply management. Healthcare consumption patterns remained predictable, encouraging manufacturers to align production closely with confirmed orders. Inventory control strategies across the supply chain limited excess material circulation, supporting price stability. Export interest from international pharmaceutical markets contributed to tighter availability within the region.
Q2 2025:
Methyldopa price index behavior in North America was influenced by healthcare sector requirements and disciplined pharmaceutical production planning. Manufacturers aligned output closely with prescription-based demand, operating within structured frameworks designed to ensure supply continuity. Inventory levels were managed strategically across manufacturers and distributors to meet healthcare obligations without disruption. Logistics coordination played a critical role in supporting timely deliveries across domestic markets.
Specific methyldopa historical data within the United States and Canada can also be provided.
| Region | Countries Covered |
|---|---|
| North America | United States and Canada |
Middle East and Africa Methyldopa Price Trend
Q3 2025:
As per the methyldopa price chart, the prices in the Middle East and Africa fluctuated due to a complex interplay of factors, primarily driven by supply chain disruptions, seasonal demand shifts, and geopolitical influences.
Q2 2025:
The report explores the methyldopa pricing trends in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices.
In addition to region-wise data, information on methyldopa prices for countries can also be provided.
| Region | Countries Covered |
|---|---|
| Middle East & Africa | Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco, among other Middle Eastern and African countries. |
Asia Pacific Methyldopa Price Trend
Q3 2025:
Asia Pacific methyldopa markets exhibited mixed pricing trends due to varying demand conditions and production capacities across countries. Manufacturing hubs maintained strong output capabilities, supporting export-oriented supply flows. In some markets, controlled production schedules and firm pharmaceutical demand supported pricing, while others experienced pressure from readily available inventories. Export activity played a critical role in redistributing supply across regional and global markets.
Q2 2025:
Asia Pacific methyldopa pricing reflected varied regional demand patterns supported by strong production capacity in key manufacturing hubs. Export-oriented supply flows played a central role in determining material availability across consuming markets. Buyers emphasized procurement efficiency, supplier consistency, and quality assurance in sourcing decisions. Regional trade benefited from stable logistics networks and established export channels, supporting predictable supply flows. Inventory planning varied by market, depending on healthcare demand visibility and procurement cycles.
This methyldopa price analysis can be expanded to include a comprehensive list of countries within the region.
| Region | Countries Covered |
|---|---|
| Asia Pacific | China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand, among other Asian countries. |
Latin America Methyldopa Price Trend
Q3 2025:
Latin American methyldopa prices reflected a bearish environment influenced by subdued pharmaceutical demand and efficient supply chain operations. Improved logistics and port accessibility enhanced material availability across key markets. Buyers delayed procurement decisions, relying on existing stocks and short-term sourcing strategies. Import competition intensified as multiple suppliers targeted regional demand, increasing pressure on transactional pricing. Healthcare distributors focused on cost control and inventory optimization amid budgetary considerations.
Q2 2025:
In Latin America, methyldopa pricing conditions were shaped by pharmaceutical demand planning and competitive import availability. Distributors emphasized stock management strategies to align inventory levels with healthcare consumption requirements. Buyers coordinated procurement with hospital supply schedules and prescription forecasts. Competitive participation from multiple international suppliers influenced sourcing decisions and contract negotiations. Supply chain coordination, including port operations and inland logistics, played a central role in material accessibility.
This comprehensive review can be extended to include specific countries within the region.
| Region | Countries Covered |
|---|---|
| Latin America | Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru, among other Latin American countries. |
Methyldopa Pricing Report, Market Analysis, and News
IMARC's latest publication, “Methyldopa Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2025 Edition,” presents a detailed examination of the methyldopa market, providing insights into both global and regional trends that are shaping prices. This report delves into the spot price of methyldopa at major ports and analyzes the composition of prices, including FOB and CIF terms. It also presents detailed methyldopa prices trend analysis by region, covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The factors affecting methyldopa pricing, such as the dynamics of supply and demand, geopolitical influences, and sector-specific developments, are thoroughly explored. This comprehensive report helps stakeholders stay informed with the latest market news, regulatory updates, and technological progress, facilitating informed strategic decision-making and forecasting.
Methyldopa Industry Analysis
The global methyldopa market is expected to grow at a CAGR of 3.06% during 2026-2034. The market is primarily driven by consistent demand for antihypertensive medications, expanding access to regulated healthcare systems, and stable pharmaceutical manufacturing capacity.
Latest News and Developments:
- October 2025: A network meta-analysis covering 23 clinical trials involving 3989 women assessed oral antihypertensive treatments during pregnancy. The findings showed that both labetalol and methyldopa significantly reduced severe hypertension compared with placebo or no treatment. Further analysis indicated that labetalol was associated with lower risks of preeclampsia and preterm birth when compared with nifedipine.
Product Description
Methyldopa is an antihypertensive drug used in the therapeutic management of hypertension, which is high blood pressure. This is because the drug works as an alpha-2 adrenergic agonist, which is a specific class of drugs that act on the receptors in the brain, which aids in the regulation of blood pressure through controlling blood vessels, hence reducing the pressure in the blood. Methyldopa is particularly noteworthy because it is safer for the mother and baby than most antihypertensive medicines, while being used mostly to treat high blood pressure during pregnancy. It is used selectively when other medications are useless or unsuitable for use in treating depression. Methyldopa can be given via the oral route or intravenous route and generally starts working within the first couple of hours if given. In addition, it is necessary to monitor the blood pressure and perform blood tests, from time to time, while under the medication to assess the success of the therapy and side effects.
Report Coverage
| Key Attributes | Details |
|---|---|
| Product Name | Methyldopa |
| Report Features | Exploration of Historical Trends and Market Outlook, Industry Demand, Industry Supply, Gap Analysis, Challenges, Methyldopa Price Analysis, and Segment-Wise Assessment. |
| Currency/Units | US$ (Data can also be provided in local currency) or Metric Tons |
| Region/Countries Covered | The current coverage includes analysis at the global and regional levels only. Based on your requirements, we can also customize the report and provide specific information for the following countries: Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand* Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal and Greece* North America: United States and Canada Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru* Middle East & Africa: Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco* *The list of countries presented is not exhaustive. Information on additional countries can be provided if required by the client. |
| Information Covered for Key Suppliers |
|
| Customization Scope | The report can be customized as per the requirements of the customer |
| Report Price and Purchase Option |
Plan A: Monthly Updates - Annual Subscription
Plan B: Quarterly Updates - Annual Subscription
Plan C: Biannually Updates - Annual Subscription
|
| Post-Sale Analyst Support | 360-degree analyst support after report delivery |
| Delivery Format | PDF and Excel through email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Benefits for Stakeholders:
- IMARC’s report presents a detailed analysis of methyldopa pricing, covering global and regional trends, spot prices at key ports, and a breakdown of Ex Works, FOB, and CIF prices.
- The study examines factors affecting methyldopa price trend, including raw material costs, supply-demand shifts, geopolitical impacts, and industry developments, offering insights for informed decision-making.
- The competitive landscape review equips stakeholders with crucial insights into the latest market news, regulatory changes, and technological advancements, ensuring a well-rounded, strategic overview for forecasting and planning.
- IMARC offers various subscription options, including monthly, quarterly, and biannual updates, allowing clients to stay informed with the latest market trends, ongoing developments, and comprehensive market insights. The methyldopa price charts ensure our clients remain at the forefront of the industry.
Need more help?
- Speak to our experienced analysts for insights on the current market scenarios.
- Include additional segments and countries to customize the report as per your requirement.
- Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
- For further assistance, please connect with our analysts.
Request Customization
Inquire Before Buying
Speak to an Analyst
Request Brochure
Benefits of Customization
- Personalize this research
- Triangulate with your data
- Get data as per your format and definition
- Gain a deeper dive into a specific application, geography, customer, or competitor
- Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-201-971-6302
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-714-6104
Email: sales@imarcgroup.com
Client Testimonials
.webp)
.webp){kind=logo}
Why Choose Us
IMARC offers trustworthy, data-centric insights into commodity pricing and evolving market trends, enabling businesses to make well-informed decisions in areas such as procurement, strategic planning, and investments. With in-depth knowledge spanning more than 1000 commodities and a vast global presence in over 150 countries, we provide tailored, actionable intelligence designed to meet the specific needs of diverse industries and markets.
1000
+Commodities
150
+Countries Covered
3000
+Clients
20
+Industry
Robust Methodologies & Extensive Resources
IMARC delivers precise commodity pricing insights using proven methodologies and a wealth of data to support strategic decision-making.
Subscription-Based Databases
Our extensive databases provide detailed commodity pricing, import-export trade statistics, and shipment-level tracking for comprehensive market analysis.
Primary Research-Driven Insights
Through direct supplier surveys and expert interviews, we gather real-time market data to enhance pricing accuracy and trend forecasting.
Extensive Secondary Research
We analyze industry reports, trade publications, and market studies to offer tailored intelligence and actionable commodity market insights.
Trusted by 3000+ industry leaders worldwide to drive data-backed decisions. From global manufacturers to government agencies, our clients rely on us for accurate pricing, deep market intelligence, and forward-looking insights.